We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI-Powered Whole-Slide Image Analyzer Predicts Immunotherapy Response for Rare Cancer Patients

By LabMedica International staff writers
Posted on 13 Nov 2024
Print article
Image: SCOPE IO has shown promise in predicting immunotherapy response in rare cancer patients (Photo courtesy of Lunit)
Image: SCOPE IO has shown promise in predicting immunotherapy response in rare cancer patients (Photo courtesy of Lunit)

Immunotherapy, especially immune checkpoint inhibitors like pembrolizumab, has become a groundbreaking treatment for cancer patients. However, not all patients respond the same way to this therapy, and identifying who will benefit the most remains a challenge, particularly in the case of rare tumor types where treatment options and research data are sparse. Now, a new study has highlighted the potential of using artificial intelligence (AI) to assess the tumor microenvironment to predict treatment responses in patients with rare cancers receiving pembrolizumab.

In the study, researchers at The University of Texas MD Anderson Cancer Center (Houston, TX, USA) utilized Lunit’s (Seoul, South Korea) AI-powered whole-slide image analyzer, Lunit SCOPE IO, to examine tumor microenvironment characteristics in biopsies taken both before and during treatment from patients with rare tumors undergoing pembrolizumab therapy. The study involved the analysis of over 500 slides from more than 10 different rare tumor types. The results suggest that Lunit SCOPE IO can effectively detect specific patterns in tumor samples that are linked to more favorable treatment outcomes. Patients whose tumors exhibited AI-detected changes in intratumoral immune cells (tumor-infiltrating lymphocytes; iTIL) and tumor content were significantly more likely to show positive responses to immunotherapy. These groundbreaking research findings reveal the potential of AI to predict how well patients with rare cancers will respond to immunotherapy treatments.

"These findings highlight how our AI technology can provide deep insights into the unique and challenging tumor microenvironment seen in rare cancers, and represent a critical advancement in our understanding of rare tumor biology," said Brandon Suh, CEO of Lunit. "This study has demonstrated the value of Lunit SCOPE IO in an important clinical setting, showcasing its potential to personalize treatment for patients who have limited therapeutic options. We believe these advancements are a testament to the transformative impact AI can have on oncology and patient outcomes."

Related Links:
Lunit
The University of Texas MD Anderson Cancer Center

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Tabletop Centrifuge
Mikro 185
New
Malaria Rapid Test
OnSite Malaria Pf/Pan Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.